Advicenne (ALDVI) Stock Overview
A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ALDVI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Advicenne S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.84 |
| 52 Week High | €2.20 |
| 52 Week Low | €1.10 |
| Beta | 0.91 |
| 1 Month Change | 5.63% |
| 3 Month Change | 14.16% |
| 1 Year Change | -6.42% |
| 3 Year Change | -68.85% |
| 5 Year Change | -82.33% |
| Change since IPO | -86.87% |
Recent News & Updates
Shareholder Returns
| ALDVI | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 4.4% | -1.2% | 1.4% |
| 1Y | -6.4% | -12.4% | 8.9% |
Return vs Industry: ALDVI exceeded the French Pharmaceuticals industry which returned -11.4% over the past year.
Return vs Market: ALDVI underperformed the French Market which returned 8.6% over the past year.
Price Volatility
| ALDVI volatility | |
|---|---|
| ALDVI Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 10.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALDVI's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALDVI's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 13 | Didier Laurens | www.advicenne.com |
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures.
Advicenne S.A. Fundamentals Summary
| ALDVI fundamental statistics | |
|---|---|
| Market cap | €26.04m |
| Earnings (TTM) | -€9.70m |
| Revenue (TTM) | €5.90m |
Is ALDVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALDVI income statement (TTM) | |
|---|---|
| Revenue | €5.90m |
| Cost of Revenue | €6.86m |
| Gross Profit | -€962.00k |
| Other Expenses | €8.73m |
| Earnings | -€9.70m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | -16.32% |
| Net Profit Margin | -164.45% |
| Debt/Equity Ratio | -77.8% |
How did ALDVI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 11:37 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Advicenne S.A. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephanie Lefebvre | Gilbert Dupont |
| Jean-Pierre Loza | In Extenso Financement & Marché |
| Jean-Pierre Tabart | TPICAP Midcap |